708I wont rehash what I've previously posted but if you adjust...

708

I wont rehash what I've previously posted but if you adjust for the revenue coming from the UK acquisition, which from memory settled in December last year then they actually made very little progress with growing revenue in the March quarter compared to the corresponding quarter last year and also compared to the December 2023 quarter.

I drafted up some more comprehensive comments earlier today but decided to ditch them. However basically my concern is that the lab coats might have too much sway and the Board has to bring in a marketing whizz / a business head with the authority to rework everything, including its strategy, its website(s), its brand(s), etc etc.

I thought about having a go with the MetaXplore product but everything seems duplicated so I gave up: two websites (Microba and Co-Biome), two product lines (MetaXplore and Co-Biome), I have to go through a GP (why, don't need to do so for the FIT test for bowel cancer) but the only way I can find a GP certified to be involved is by sending an email to a Co-Biome address (why not just list participating GPs by post code on the website). The test comes from Microba / Co-Biome not the GP but has to go back to the GP not the company (why, maybe for the results but why the sample?). This whole process needs to be stripped down and simplified and I think the current management needs a rocket - a quiet word from Sonic might be timely.